Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
06/2002
06/25/2002US6410552 Benzoether and related compositions and methods
06/25/2002US6410544 Vision defects; administering pilocarpine
06/25/2002US6410540 Inhibitors of p38-αkinase
06/25/2002US6410534 Anticancer agents
06/25/2002US6410526 Bone disorders; restenosis; vision disorders; anticholesterol agents; anticancer, antitumor agents
06/25/2002US6410289 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
06/25/2002CA2220024C Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048190A1 Use of l-carnitine as stabilizing agent of proteins
06/20/2002WO2002048148A2 Pyrazolopyridine derivatives
06/20/2002WO2002048134A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002WO2002048117A1 Quinazolinone derivatives
06/20/2002WO2002048096A1 Hydrazone derivatives and use thereof in medicines
06/20/2002WO2002047762A1 Serine protease inhibitors
06/20/2002WO2002047728A2 Treatment of posterior capsule opacification
06/20/2002WO2002047708A2 Selective cox-2 inhibition from edible plant extracts
06/20/2002WO2002047704A1 Herbal pharmaceutical compositions for treating immunological disorders
06/20/2002WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
06/20/2002WO2002047694A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases
06/20/2002WO2002047493A2 Health promoting compositions
06/20/2002WO2002030888A3 Tricyclic compounds and uses thereof
06/20/2002WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases
06/20/2002WO2002012214A3 Non-imidazole aryloxyalkylamines as h3 receptor ligands
06/20/2002WO2001080825A3 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
06/20/2002WO2001056590A3 Utilization of protein kinase inhibitor alpha
06/20/2002WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
06/20/2002WO2000061596A8 50 human secreted proteins
06/20/2002WO2000052210A9 Methods for targeting rna molecules
06/20/2002US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis
06/20/2002US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition
06/20/2002US20020077358 Administering hydroxyeicosatetraenoic acid derivatives that stimulate mucin production and/or secretion in the conjunctival epithelium for the treatment of transient dry eye conditions associated with refractive surgery
06/20/2002US20020077356 Nonsteroidal antiinflammatory agents
06/20/2002US20020077343 H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use
06/20/2002US20020077340 Pyridone inhibitors of fatty acid binding protein and method
06/20/2002US20020077337 Chemical compounds
06/20/2002US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2)
06/20/2002US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis
06/20/2002US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them
06/20/2002US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
06/20/2002US20020077319 Combination of GABA agonists and aldose reductase inhibitors
06/20/2002US20020076766 Novel glucosaminidase
06/20/2002US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain
06/20/2002US20020076395 Modified adipose tissue and related implants and methods
06/20/2002DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane
06/20/2002DE10060292A1 Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibiting the Na + / H + exchanger and containing medicament
06/20/2002CA2445091A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases
06/20/2002CA2431852A1 Herbal pharmaceutical compositions for treating immunological disorders
06/20/2002CA2431406A1 Quinazolinone derivatives
06/20/2002CA2430992A1 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002CA2428216A1 Secreted proteins
06/19/2002EP1215214A1 Novel polypeptide
06/19/2002EP1214937A2 Terfenadine carboxylate and the treatment of dermal irritation
06/19/2002EP1214452A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes
06/19/2002EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic
06/19/2002EP1214346A1 A novel angiogenesis inhibitor
06/19/2002EP1214337A2 Proteins associated with cell differentiation
06/19/2002EP1214335A1 Gamma-carboxyglutamate containing conopeptides
06/19/2002EP1214326A1 Inhibitors of prenyl-protein transferase
06/19/2002EP1214318A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
06/19/2002EP1214313A2 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same
06/19/2002EP1214293A1 Non-peptidic cyclophilin binding compounds and their use
06/19/2002EP1214095A1 Use of anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions
06/19/2002EP1214072A2 Use of desloratadine for treating allergic and inflammatory conditions
06/19/2002EP1214071A2 Treating allergic and inflammatory conditions using desloratadine
06/19/2002EP1214068A1 Ophthalmic fluid
06/19/2002EP1214065A1 A method for optimizing pupil size using alpha antagonist
06/19/2002EP1214064A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
06/19/2002EP1214062A2 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
06/19/2002EP1214056A1 Topical suspension formulations containing ciprofloxacin and dexamethasone
06/19/2002EP0866691B1 Sublingual and buccal administration of selegiline
06/19/2002EP0634932B1 Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
06/19/2002CN1354670A Therapeutic agent comprising botulinum neurotoxin
06/18/2002US6407114 Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
06/18/2002US6407108 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them
06/18/2002US6407104 Pyrrolo[1,2-a]pyrazine spla2 inhibitor
06/18/2002US6407094 Glutamate receptor antagonists
06/18/2002US6407067 Salts of thrombin inhibitors
06/18/2002CA2029657C Compositions and their use in lowering intraocular pressure
06/13/2002WO2002046426A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
06/13/2002WO2002046385A2 Enzymes
06/13/2002WO2002046384A2 Kinases and phosphatases sequences, and use thereof
06/13/2002WO2002046373A1 Method of collecting placental stem cells
06/13/2002WO2002046226A2 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
06/13/2002WO2002046193A2 Heterocyclic ether substituted imidazoquinolines
06/13/2002WO2002046192A2 Thioether substituted imidazoquinolines
06/13/2002WO2002046191A2 Urea substituted imidazoquinoline ethers
06/13/2002WO2002046190A2 Sulfonamido ether substituted imidazoquinolines
06/13/2002WO2002046189A2 Aryl ether substituted imidazoquinolines
06/13/2002WO2002046188A2 Amido ether substituted imidazoquinolines
06/13/2002WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
06/13/2002WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
06/13/2002WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
06/13/2002WO2002046169A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
06/13/2002WO2002046154A1 Peroxisome proliferator activated receptor d activators
06/13/2002WO2002045737A2 Methods of treatment involving human mda-7
06/13/2002WO2002045683A2 Reversible gelling system for ocular drug delivery
06/13/2002WO2002045652A2 Tyrosine kinase inhibitors
06/13/2002WO2002019996A3 Prevention of acute sinusitis and sinus attack
06/13/2002WO2002017857A3 Methods and compositions for inhibiting angiogenesis
06/13/2002WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
1 ... 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 ... 531